


## Accepted Manuscript

Title: The changing scenario of 1<sup>st</sup> line therapy in non-oncogene addicted NSCLCs in the era of immunotherapy

Authors: A Russo, T Franchina, GRR Ricciardi, G Toscano, S Schifano, G Lo Certo, A Battaglia, E Pantò, M Scaffidi Fonti, V Adamo



PII: S1040-8428(18)30099-4  
DOI: <https://doi.org/10.1016/j.critrevonc.2018.06.007>  
Reference: ONCH 2573

To appear in: *Critical Reviews in Oncology/Hematology*

Received date: 26-2-2018  
Revised date: 23-4-2018  
Accepted date: 13-6-2018

Please cite this article as: Russo A, Franchina T, Ricciardi G, Toscano G, Schifano S, Lo Certo G, Battaglia A, Pantò E, Scaffidi Fonti M, Adamo V, The changing scenario of 1<sup>st</sup> line therapy in non-oncogene addicted NSCLCs in the era of immunotherapy, *Critical Reviews in Oncology / Hematology* (2018), <https://doi.org/10.1016/j.critrevonc.2018.06.007>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

# The changing scenario of 1<sup>st</sup> line therapy in non-oncogene addicted NSCLCs in the era of immunotherapy.

Russo A<sup>1</sup>, Franchina T<sup>1</sup>, Ricciardi GRR<sup>1</sup>, Toscano G<sup>1</sup>, Schifano S<sup>1</sup>, Lo Certo G<sup>1</sup>, Battaglia A<sup>1</sup>, Pantò E<sup>1</sup>, Scaffidi Fonti M<sup>1</sup>, Adamo V<sup>1\*</sup>.

<sup>1</sup>Medical Oncology Unit A.O. Papardo & Department of Human Pathology University of Messina, Italy

**\*Corresponding author:** Prof. Vincenzo Adamo

Address for correspondence: Medical Oncology Unit, A.O. Papardo, Contrada Papardo, 98158, Messina (Italy).

Telephone number: +39 0903996150

Fax number: +39 0903996307

Email address: vadamo@unime.it

**Grant Support:** This work was supported by the Consorzio Interuniversitario Nazionale per la Bio-Oncologia (CINBO), A.S.S.O. (Associazione Siciliana Sostegno Oncologico) Onlus and Borsa Dottorati FSE XXXII Ciclo Unime.

## HIGHLIGHTS

- 1<sup>st</sup> line treatment of NSCLC is a rapidly evolving therapeutic paradigm
- Pembrolizumab is the first-in-class ICI approved in chemotherapy-naïve NSCLCs
- Several ICIs are currently under evaluation either alone or in various combinations
- The results of ongoing phase III trials will reshape the upfront therapy of NSCLC

## ABSTRACT

During the last two decades front-line treatment of metastatic Non Small Cell Lung Cancer (NSCLC) has profoundly changed moving from the old “one size fits all” concept to a “histology-based” approach and then, for a small subgroup of patients to a “molecularly-selected” one. The development of immune checkpoint inhibitors and the unprecedented results reported in 2<sup>nd</sup>/3<sup>rd</sup> line prompted the evaluation of these novel therapeutic agents in chemotherapy-naïve patients either alone or in combination with platinum-based chemotherapy. Several randomized trials are evaluating the impact of immune-checkpoint inhibitors in 1<sup>st</sup> line and some of them have yet produced preliminary evidence of efficacy. However, still a long way to go and several questions are still unanswered, including proper patients selection, optimal sequential/combinatorial use of these agents, appropriate treatment duration, and finally the identification of predictive biomarkers. The aim of this paper is to provide a comprehensive overview on the growing role of

Download English Version:

<https://daneshyari.com/en/article/8733503>

Download Persian Version:

<https://daneshyari.com/article/8733503>

[Daneshyari.com](https://daneshyari.com)